A computational hypothesis for allostasis: Delineation of substance dependence, conventional therapies, and alternative treatments

Frontiers in Psychiatry

Volumn 4, Issue DEC, 2013, Pages

  Levy, Yariv Z ^a   Levy, Dino J ^b   Barto, Andrew G ^a   Meyer, Jerrold S ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allostasis; Antireward system adaptations; Drug addition; Drug intake prediction; Knowledge repository model; Mood; Multiscale computational model; Reward system adaptations

Indexed keywords

ANTIDEPRESSANT AGENT; NICOTINE DERIVATIVE; NICOTINE GUM; NICOTINE PATCH;

ALLOSTASIS; ALTERNATIVE MEDICINE; ANIMAL BEHAVIOR; ANTERIOR CINGULATE; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR THERAPY; BRAIN FUNCTION; COGNITION; COGNITIVE THERAPY; COMPULSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG SELF ADMINISTRATION; DRUG USE; DRUG WITHDRAWAL; GUIDED IMAGERY; HUMAN; MATHEMATICAL ANALYSIS; MEDITATION; MINDFULNESS; MOOD; NEUROPSYCHOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PATIENT COUNSELING; PREDICTION; PREFRONTAL CORTEX; RELAXATION TRAINING; REMISSION; REWARD; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VENTRAL TEGMENTUM;

EID: 84891666346     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00167     Document Type: Article

References (80)

1. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason J editors. Handbook of Life Stress Cognition and Health. Oxford: Wiley & Sons (1998). p. 629-49.
2. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology (2001) 24(2):97-129. doi: 10.1016/S0893-133X(00)00195-0.
3. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science (1997) 278(5335):52-8. doi:10.1126/science.278.5335.52.
4. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science (1998) 242(4879):715-23. doi:10.1126/science.2903550.
5. Ahmed SH, Kenny PJ, Koob GF, Markou A. Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci (2002) 5(7):625-6. doi:10.1038/nn872.
6. Camí J, Farré M. Mechanisms of disease: drug addiction. N Engl J Med (2003) 349(10):975-86. doi:10.1056/NEJMra023160.
7. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol (2008) 59:29-53. doi:10.1146/annurev.psych.59.103006.093548.
8. Ahmed SH, Koob GF. Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology (2005) 180(3):473-90. doi:10.1007/s00213-005-2180-z.
9. Koob GF. A role for brain stress systems in addiction. Neuron (2008) 59(1):11-34. doi:10.1016/j.neuron.2008.06.012.
10. George O, Le Moal M, Koob GF. Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems. Physiol Behav (2012) 106(1):58-64. doi:10.1016/j.physbeh.2011.11.004.
11. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci (2005) 8(11):1442-4. doi:10.1038/nn1105-1442.
12. Levy YZ, Levy D, Meyer JS. Computational hypothesis for maturing out of addiction and mindfulness-based cognitive techniques. In: Samsonovich AV, Jóhannsdóttir KR editors. Biologically Inspired Cognitive Architectures 2011-Proceedings of the Second Annual Meeting of the BICA Society. Amsterdam: IOS Press (2011). p. 222-31.
13. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci (1996) 19:319-40. doi:10.1146/annurev.ne.19.030196.001535.
14. Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change in hedonic set point. Science (1998) 282(5387):298-300. doi:10.1126/science.282.5387.298.
15. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry (2002) 159(10):1642-52. doi:10.1176/appi.ajp.159.10.1642.
16. Yurica CL, DiTomasso RA. Cognitive distortions. In: Freeman A, Felgoise SH, Nezu CM, Nezu AM, Reinecke MA editors. Encyclopedia of Cognitive Behavior Therapy. New York: Springer (2005). p. 117-22.
17. Morgenstern J, McCrady BS. Curative factors in alcohol and drug treatment: behavioral and disease model perspectives. Br J Addict (1992) 87(6):901-12. doi:10.1111/j.1360-0443.1992.tb01985.x.
18. Chase HW, Clark L. Gambling severity predicts midbrain response to near-miss outcomes. J Neurosci (2010) 30(18):6180-7. doi:10.1523/JNEUROSCI.5758-09.2010.
19. Fortune EE, Goodie AS. Cognitive distortions as a component and treatment focus of pathological gambling: a review. Psychol Addict Behav (2012) 26(2):298-310. doi:10.1037/a0026422.
20. Powers PS, Perez A, Boyd F, Rosemurgy A. Eating pathology before and after bariatric surgery: a prospective study. Int J Eat Disord (1999) 25(3):293-300. doi:10.1002/(SICI)1098-108X(199904)25:3<293::AID-EAT7>3.0.CO;2-G.
21. Davis RA. A cognitive-behavioral model of pathological Internet use. Comput Hum Behav (2001) 17(2):187-95. doi:10.1080/00207594.2010.541256.
22. Barto AG. Adaptive critics and the basal ganglia. In: Houk JC, Davis JL, Beiser DG editors. Models of Information Processing in the Basal Ganglia. Cambridge, MA: MIT Press (1995). p. 215-32.
23. Houk JC, Adams JL, Barto AG. A model of how the basal ganglia generate and use neural signals that predict reinforcement. In: Houk JC, Davis JL, Beiser DG editors. Models of Information Processing in the Basal Ganglia. Cambridge, MA: MIT Press (1995). p. 249-70.
24. Levy YZ, Levy D, Meyer JS, Siegelmann HT. Drug addiction: a computational multiscale model combining neuropsychology, cognition, and behavior. In: Encarnação P, Veloso A editors. Proceedings of the International Conference on Bio-inspired Systems and Signal Processing. Portugal: INSTICC Press (2009). p. 87-94.
25. Robinson T, Berridge K. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev (1993) 18(3):247-291. doi:10.1016/0165-0173(93)90013-P.
26. Sloan FA, Wang Y. Economic theory and evidence on smoking behavior of adults. Addiction (2008) 103(11):1777-85. doi:10.1111/j.1360-0443.2008.02329.x.
27. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci (2011) 12(11):652-69. doi:10.1038/nrn3119.
28. Volkow ND, Wang G-J, Fowler JS, Tomasi D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol (2012) 52:321-36. doi:10.1146/annurev-pharmtox-010611-134625.
29. Hodgins DC, El-Guebaly N, Armstrong S. Prospective and retrospective reports of mood states before relapse to substance use. J Consult Clin Psych (1995) 63(3):400-7. doi:10.1037/0022-006X.63.3.400.
30. Aston-Jones G, Harris GC. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology (2004) 47(Suppl 1):167-79. doi:10.1016/j.neuropharm.2004.06.020.
31. De Alba I, Samet JH, Saitz R. Burden of medical illness in drug-and alcohol-dependent persons without primary care. Am J Addict (2004) 13(1):33-45. doi:10.1080/10550490490265307.
32. Kalivas PW, Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse (1990) 5(1):48-58. doi:10.1002/syn.890050104.
33. Heidbreder CA, Thompson AC, Shippenberg TS. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther (1996) 278(2):490-502.
34. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry (1999) 156(1):19-26.
35. Erb S, Shaham Y, Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology (1996) 128(4):408-12. doi:10.1007/s002130050150.
36. Sinha R, Fuse T, Aubin LR, O'Malley SS. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (2000) 152(2):140-8. doi:10.1007/s002130000499.
37. Pollini RA, McCall L, Mehta SH, Vlahov D, Strathdee SA. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend (2006) 83(2):104-10. doi:10.1016/j.drugalcdep.2005.10.015.
38. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. Ann Behav Med (2006) 32(1):10-20. doi:10.1207/s15324796abm3201_2.
39. de Wit H, Stewart J. Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology (1983) 79(1):29-31. doi:10.1007/BF00433012.
40. Spealman RD, Barrett-Larimore RL, Rowlett JK, Platt DM, Khroyan TV. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol Biochem Behav (1999) 64(2):327-36. doi:10.1016/S0091-3057(99)00049-0.
41. See RE. Neural substrates of conditioned-cued relapse to drug-seeking behavior. Pharmacol Biochem Behav (2002) 71(3):517-29. doi:10.1016/S0091-3057(01)00682-7.
42. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry (2005) 162(8):1414-22. doi:10.1176/appi.ajp.162.8.1414.
43. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol (2003) 54:25-53. doi:10.1146/annurev.psych.54.101601.145237.
44. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2008) 1:CD000146. doi:10.1002/14651858.CD000146.pub3.
45. Brewer JA, Mallik S, Babuscio TA, Nich C, Johnson HE, Deleone CM, et al. Mindfulness training for smoking cessation: results from a randomized controlled trial. Drug Alcohol Depend (2011) 119(1-2):72-80. doi:10.1016/j.drugalcdep.2011.05.027.
46. Muzic RF, Berridge MS, Friedland RP, Zhu N, Nelson AD. PET quantification of specific binding of carbon-11-nicotine in human brain. J Nucl Med (1998) 39(12):2048-54.
47. DiFranza JR, Wellman RJ, Savageau JA. Does progression through the stages of physical addiction indicate increasing overall addiction to tobacco? Psychopharmacology (2012) 219(3):815-22. doi:10.1007/s00213-011-2411-4.
48. Bobashev G, Costenbader E, Gutkin BS. Comprehensive mathematical modeling in drug addiction sciences. Drug Alcohol Depend (2007) 89(1):102-6. doi:10.1016/j.drugalcdep.2006.12.029.
49. Kitano H. Systems biology: a brief overview. Science (2002) 295(5560):1662-4. doi:10.1126/science.1069492.
50. Meyer JS, Quenzer LF. Psychopharmacology: Drugs, the Brain, and Behavior. Sunderland, MA: Sinauer (2005).
51. Gutkin BS, Dehaene S, Changeux J-P. A neurocomputational hypothesis for nicotine addiction. Proc Natl Acad Sci U S A (2006) 103(4):1106-11. doi:10.1073/pnas.0510220103.
52. Levy D, Levy YZ, Siegelmann HT. Modeling addiction in terms of fluctuating neurotransmitters within the reward system. Tech Rep UMass Amherst (2011).
53. Kovatchev B, Breton M, Johnson B. In silico models of alcohol dependence and treatment. Front Psychiatry (2012) 3:4. doi:10.3389/fpsyt.2012.00004.
54. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry (2005) 162(8):1483-93. doi:10.1176/appi.ajp.162.8.1483.
55. Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, et al. The genetics of addiction-a translational perspective. Transl Psychiatry (2012) 2:e140. doi:10.1038/tp.2012.54.
56. Levy YZ, Levy D, Meyer JS, Siegelmann HT. Identification and control of intrinsic bias in a multiscale computational model of drug addiction. In: Shin SY, Ossowski S, Schumacher M, Palakal MJ, Hung C-C editors. Proceedings of the 2010 ACM Symposium on Applied Computing. New York: ACM (2010). p. 2389-93.
57. Tang Y-Y, Lu Q, Fan M, Yang Y, Posner MI. Mechanisms of white matter changes induced by meditation. Proc Natl Acad Sci U S A (2012) 109(26):10570-4. doi:10.1073/pnas.1207817109.
58. Xue YX, Luo YX, Wu P, Shi HS, Xue LF, Chen C, et al. A memory retrieval-extinction procedure to prevent drug craving and relapse. Science (2012) 336(6078):241-5. doi:10.1126/science.1215070.
59. Milton AL, Everitt BJ. Wiping drug memories. Science (2012) 336(6078):167-8. doi:10.1126/science.1221691.
60. Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control (2013) 22(1):32-7. doi:10.1136/tobaccocontrol-2011-050129.
61. Bolt DM, Piper ME, Theobald WE, Baker TB. Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol (2012) 80(1):54-65. doi:10.1037/a0026366.
62. Thompson GH, Hunter DA. Nicotine replacement therapy. Ann Pharmacother (1998) 32(10):1067-75. doi:10.1345/aph.17382.
63. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA (1994) 271(24):1940-7.
64. U.S. Department of Health and Human Services, Public Health Service. Treating Tobacco Use and Dependence: 2008 Update-Clinical Practice Guideline. (2008). Available from: http://www.ahrq.gov/clinic/tobacco/treating_tobacco_use08.pdf.
65. Loh WY, Piper ME, Schlam TR, Fiore MC, Smith SS, Jorenby DE, et al. Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. Nicotine Tob Res (2012) 14(2):131-41. doi:10.1093/ntr/ntr147.
66. McCarthy DE, Piasecki TM, Jorenby DE, Lawrence DL, Shiffman S, Baker TB. A multi-level analysis of non-significant counseling effects in a randomized smoking cessation trial. Addiction (2010) 105(12):2195-208. doi:10.1111/j.1360-0443.2010.03089.x.
67. Beck AT. Cognitive therapy. A 30-year retrospective. Am Psychol (1991) 46(4):368-75. doi:10.1037/0003-066X.46.4.368.
68. Childress A, Burns D. The basics of cognitive therapy. Psychosomatics (1981) 22(12):1017-27. doi:10.1016/S0033-3182(81)73443-1.
69. Kendall PC, Hollon SD. Cognitive-behavioral interventions: overview and current status. In: Kendall PC, Hollon SD editors. Cognitive-Behavioral Interventions: Theory, Research and Procedures. New York: Academic Press. (1979). p. 1-13.
70. U.S. Department of Health and Human Services, National Institutes of Health, National Center for Complementary and Alternative Medicine. What is Complementary and Alternative Medicine? (2008). Available from: http://nccam.nih.gov/sites/nccam.nih.gov/files/D347_05-25-2012.pdf.
71. Hendricks PS, Delucchi KL, Hall SM. Mechanisms of change in extended cognitive behavioral treatment for tobacco dependence. Drug Alcohol Depend (2010) 109(1-3):114-9. doi:10.1016/j.drugalcdep.2009.12.021.
72. Hathaway KM, Erasmus Y. Integrative therapies for tobacco cessation. In: Chlan L, Hertz MI editors. Integrative Therapies in Lung Health and Sleep. New York: Springer (2012). p. 223-46.
73. Bowen S, Chawla N, Collins SE, Witkiewitz K, Hsu S, Grow J, et al. Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abus (2009) 30(4):295-305. doi:10.1080/08897070903250084.
74. Leshner AI. Addiction is a brain disease, and it matters. Science (1997) 278(5335):45-7. doi:10.1126/science.278.5335.45.
75. Buchman DZ, Illes J, Reiner PB. The paradox of addiction neuroscience. Neuroethics (2011) 4(2):65-77. doi:10.1007/s12152-010-9079-z.
76. Engel GL. The need for a new medical model: a challenge for biomedicine. Science (1977) 196(4286):129-36. doi:10.1126/science.847460.
77. Leukefeld CG, Leukefeld S. Primary socialization theory and a bio/psycho/social/spiritual practice model for substance use. Subst Use Misuse (1999) 34(7):983-91. doi:10.3109/10826089909039390.
78. Buchman DZ, Skinner W, Illes J. Negotiating the relationship between addiction, ethics, and brain science. AJOB Neurosci (2010) 1(1):36-45. doi:10.1080/21507740903508609.
79. Heyman GM. Addiction: a Disorder of Choice. Cambridge, MA: Harvard UP (2010).
80. Tretter F, Gebicke-Haerter PJ, Albus M, Van der Heiden U, Schwegler H. Systems biology and addiction. Pharmacopsychiatry (2009) 42:S11-33. doi:10.1055/s-0029-1220699.